Information Provided By:
Fly News Breaks for April 17, 2018
HOLX
Apr 17, 2018 | 14:28 EDT
Goldman Sachs analyst Isaac Ro believes the financial impact of LightRx Face & Body's partnership for the SculptSure platform will be "de minimus" to total Hologic revenues, but he still views the news as a positive given the struggles in Cynosure's business since the acquisition of the company. Ro maintains a Buy rating and $43 price target on Hologic shares.
News For HOLX From the Last 2 Days
There are no results for your query HOLX
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.